Kinetic exclusion assay

Last updated
Figure 1. A fraction of receptor not bound to ligand in solution is captured by the ligand coated solid phase and subsequently labelled with a fluorescent secondary antibody. Figure 1 Assay Format.jpg
Figure 1. A fraction of receptor not bound to ligand in solution is captured by the ligand coated solid phase and subsequently labelled with a fluorescent secondary antibody.

A kinetic exclusion assay (KinExA) is a type of bioassay in which a solution containing receptor, ligand, and receptor-ligand complex is briefly exposed to additional ligand immobilized on a solid phase. [1] [2]

Contents

Description

During the assay, a fraction of the free receptor is captured by the solid phase ligand and subsequently labeled with a fluorescent secondary molecule (Figure 1). [1] [2] The short contact time with the solid phase does not allow significant dissociation of the pre-formed complexes in the solution. [3] Solution dissociation is thus “kinetically excluded” from contributing to the captured receptor and the resulting signal provides a measure of the free receptor in the solution.

Measuring the free receptor as a function of total ligand in a series of equilibrated solutions enables calculation of the equilibrium dissociation constant (Kd). [1] [2] [3] [4] [5] [6] [7] [8] Measuring the free receptor with several points before equilibrium enables measurement of the association rate constant (kon). The off rate (koff) can also be directly measured, however it is usually calculated from the measured Kd and measured kon, (koff = Kd * kon).

Kinetic exclusion assays have been used to measure Kd’s in the nanomolar to femtomolar range. [4] [5] [6] [7] [9] [10]

Applications

Figure 2. Example of signal generation. 1) Beads Load. 2) Equilibrated solution passes over column. 3) Introduction of secondary label. 4) Fluorescent emission of captured free receptor. Timeline figure 2.jpg
Figure 2. Example of signal generation. 1) Beads Load. 2) Equilibrated solution passes over column. 3) Introduction of secondary label. 4) Fluorescent emission of captured free receptor.

Because the fluorescent secondary molecule is applied after capture of the free receptor from solution (Figure 2) the binding constants measured using a kinetic exclusion assay are for unmodified molecules in solution and thus more accurately reflects endogenous binding interactions than methods requiring modification (typically labeling or immobilization) before measurement. [1] [2] Kinetic exclusion assays have been performed using unpurified molecules, [4] [5] in serum, [7] and have measured binding to cell membrane proteins on intact whole cell [8] [11] which brings the measured binding interactions closer to their endogenous state.

Molecules suited for measurement by KinExA are antibodies, [4] [7] [12] [13] [14] recombinant proteins, [15] [16] [17] small molecules, [6] [18] [19] [20] aptamers, [21] [22] lipids, [23] [24] nanobodies, [25] and toxins. [12] [26] [27]

Kinetic exclusion assay have also been applied for concentration immunoassay, where it has proven capable of providing the maximum theoretical, Kd limited, sensitivity. [28] [29] An example of this technique has been employed for sensitive detection of environmental contaminants i n near real-time. [30]

Standard equilibrium affinity analysis

A series of samples are prepared with all the same receptor (R) concentration but in which the ligand (L) concentration is titrated. After equilibrium is reached each sample is measured by flowing it through the column (Figure 2).

For 1:1 reversible binding Equilibrium Kd is defined as

(1) Kd≡koff/kon =R*L/RL

the binding is reversible so conservation of mass can be written as

(2) RT = R+RL

(3) LT = L +RL

Where:

Kd = equilibrium dissociation constant

kon = forward rate constant

koff = reverse rate constant

R = free receptor site concentration at equilibrium

L = free ligand site concentration at equilibrium

RL = concentration of complex at equilibrium

RT= total concentration of receptors

LT = total concentration of ligand

A simple equation [1] [2] relating the free fraction of R (=R/RT) to the Kd and LT is then fit to the measured data to find the Kd of the interaction.

Rate constant analysis

To measure the rate constants, known concentrations of receptor and ligand are mixed in solution and the quantity of free receptor is repeatedly measured over time as the solution phase reaction occurs. The time course of the free receptor depletion is then fit with a standard bimolecular rate equation.

(4) dLR/dt = kon∙R∙L - Kd∙kon∙RL

where Kd * kon has been substituted for koff .

Related Research Articles

<span class="mw-page-title-main">ELISA</span> Method to detect an antigen using an antibody and enzyme

The enzyme-linked immunosorbent assay (ELISA) is a commonly used analytical biochemistry assay, first described by Eva Engvall and Peter Perlmann in 1971. The assay is a solid-phase type of enzyme immunoassay (EIA) to detect the presence of a ligand in a liquid sample using antibodies directed against the ligand to be measured. ELISA has been used as a diagnostic tool in medicine, plant pathology, and biotechnology, as well as a quality control check in various industries.

<span class="mw-page-title-main">Immunoassay</span> Biochemical test for a protein or other molecule using an antibody

An immunoassay (IA) is a biochemical test that measures the presence or concentration of a macromolecule or a small molecule in a solution through the use of an antibody (usually) or an antigen (sometimes). The molecule detected by the immunoassay is often referred to as an "analyte" and is in many cases a protein, although it may be other kinds of molecules, of different sizes and types, as long as the proper antibodies that have the required properties for the assay are developed. Analytes in biological liquids such as serum or urine are frequently measured using immunoassays for medical and research purposes.

A protein microarray is a high-throughput method used to track the interactions and activities of proteins, and to determine their function, and determining function on a large scale. Its main advantage lies in the fact that large numbers of proteins can be tracked in parallel. The chip consists of a support surface such as a glass slide, nitrocellulose membrane, bead, or microtitre plate, to which an array of capture proteins is bound. Probe molecules, typically labeled with a fluorescent dye, are added to the array. Any reaction between the probe and the immobilised protein emits a fluorescent signal that is read by a laser scanner. Protein microarrays are rapid, automated, economical, and highly sensitive, consuming small quantities of samples and reagents. The concept and methodology of protein microarrays was first introduced and illustrated in antibody microarrays in 1983 in a scientific publication and a series of patents. The high-throughput technology behind the protein microarray was relatively easy to develop since it is based on the technology developed for DNA microarrays, which have become the most widely used microarrays.

<span class="mw-page-title-main">Host–guest chemistry</span> Supramolecular structures held together other than by covalent bonds

In supramolecular chemistry, host–guest chemistry describes complexes that are composed of two or more molecules or ions that are held together in unique structural relationships by forces other than those of full covalent bonds. Host–guest chemistry encompasses the idea of molecular recognition and interactions through non-covalent bonding. Non-covalent bonding is critical in maintaining the 3D structure of large molecules, such as proteins and is involved in many biological processes in which large molecules bind specifically but transiently to one another.

<span class="mw-page-title-main">T-cell receptor</span> Protein complex on the surface of T cells that recognizes antigens

The T-cell receptor (TCR) is a protein complex found on the surface of T cells, or T lymphocytes, that is responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules. The binding between TCR and antigen peptides is of relatively low affinity and is degenerate: that is, many TCRs recognize the same antigen peptide and many antigen peptides are recognized by the same TCR.

<span class="mw-page-title-main">Ligand (biochemistry)</span> Substance that forms a complex with a biomolecule

In biochemistry and pharmacology, a ligand is a substance that forms a complex with a biomolecule to serve a biological purpose. The etymology stems from Latin ligare, which means 'to bind'. In protein-ligand binding, the ligand is usually a molecule which produces a signal by binding to a site on a target protein. The binding typically results in a change of conformational isomerism (conformation) of the target protein. In DNA-ligand binding studies, the ligand can be a small molecule, ion, or protein which binds to the DNA double helix. The relationship between ligand and binding partner is a function of charge, hydrophobicity, and molecular structure.

The Scatchard equation is an equation used in molecular biology to calculate the affinity and number of binding sites of a receptor for a ligand. It is named after the American chemist George Scatchard.

<span class="mw-page-title-main">Digoxigenin</span> Chemical compound

Digoxigenin (DIG) is a steroid found exclusively in the flowers and leaves of the plants Digitalis purpurea, Digitalis orientalis and Digitalis lanata (foxgloves), where it is attached to sugars, to form the glycosides.

The binding constant, or affinity constant/association constant, is a special case of the equilibrium constant K, and is the inverse of the dissociation constant. It is associated with the binding and unbinding reaction of receptor (R) and ligand (L) molecules, which is formalized as:

In biochemistry, avidity refers to the accumulated strength of multiple affinities of individual non-covalent binding interactions, such as between a protein receptor and its ligand, and is commonly referred to as functional affinity. Avidity differs from affinity, which describes the strength of a single interaction. However, because individual binding events increase the likelihood of occurrence of other interactions, avidity should not be thought of as the mere sum of its constituent affinities but as the combined effect of all affinities participating in the biomolecular interaction. A particular important aspect relates to the phenomenon of 'avidity entropy'. Biomolecules often form heterogenous complexes or homogeneous oligomers and multimers or polymers. If clustered proteins form an organized matrix, such as the clathrin-coat, the interaction is described as a matricity.

<span class="mw-page-title-main">Schild equation</span>

In pharmacology, Schild regression analysis, based upon the Schild equation, both named for Heinz Otto Schild, are tools for studying the effects of agonists and antagonists on the response caused by the receptor or on ligand-receptor binding.

The estrogen receptor test (ERT) is a laboratory test to determine whether cancer cells have estrogen receptors. This information can guide treatment of the cancer.

<span class="mw-page-title-main">Bio-layer interferometry</span> Optical biosensing technology

Bio-layer interferometry (BLI) is an optical biosensing technology that analyzes biomolecular interactions in real-time without the need for fluorescent labeling. Alongside Surface Plasmon Resonance, BLI is one of few widely available label-free biosensing technologies, a detection style that yields more information in less time than traditional processes. The technology relies on the phase shift-wavelength correlation created between interference patterns off of two unique surfaces on the tip of a biosensor. BLI has significant applications in quantifying binding strength, measuring protein interactions, and identifying properties of reaction kinetics, such as rate constants and reaction rates.

There are many methods to investigate protein–protein interactions which are the physical contacts of high specificity established between two or more protein molecules involving electrostatic forces and hydrophobic effects. Each of the approaches has its own strengths and weaknesses, especially with regard to the sensitivity and specificity of the method. A high sensitivity means that many of the interactions that occur are detected by the screen. A high specificity indicates that most of the interactions detected by the screen are occurring in reality.

A thermal shift assay (TSA) measures changes in the thermal denaturation temperature and hence stability of a protein under varying conditions such as variations in drug concentration, buffer pH or ionic strength, redox potential, or sequence mutation. The most common method for measuring protein thermal shifts is differential scanning fluorimetry (DSF) or thermofluor, which utilizes specialized fluorogenic dyes.

Antigen-antibody interaction, or antigen-antibody reaction, is a specific chemical interaction between antibodies produced by B cells of the white blood cells and antigens during immune reaction. The antigens and antibodies combine by a process called agglutination. It is the fundamental reaction in the body by which the body is protected from complex foreign molecules, such as pathogens and their chemical toxins. In the blood, the antigens are specifically and with high affinity bound by antibodies to form an antigen-antibody complex. The immune complex is then transported to cellular systems where it can be destroyed or deactivated.

A ligand binding assay (LBA) is an assay, or an analytic procedure, which relies on the binding of ligand molecules to receptors, antibodies or other macromolecules. A detection method is used to determine the presence and extent of the ligand-receptor complexes formed, and this is usually determined electrochemically or through a fluorescence detection method. This type of analytic test can be used to test for the presence of target molecules in a sample that are known to bind to the receptor.

Lanthanide probes are a non-invasive analytical tool commonly used for biological and chemical applications. Lanthanides are metal ions which have their 4f energy level filled and generally refer to elements cerium to lutetium in the periodic table. The fluorescence of lanthanide salts is weak because the energy absorption of the metallic ion is low; hence chelated complexes of lanthanides are most commonly used. The term chelate derives from the Greek word for “claw,” and is applied to name ligands, which attach to a metal ion with two or more donor atoms through dative bonds. The fluorescence is most intense when the metal ion has the oxidation state of 3+. Not all lanthanide metals can be used and the most common are: Sm(III), Eu(III), Tb(III), and Dy(III).

<span class="mw-page-title-main">Fluorescence polarization immunoassay</span> Class of invitro biochemical test

Fluorescence polarization immunoassay (FPIA) is a class of in vitro biochemical test used for rapid detection of antibody or antigen in sample. FPIA is a competitive homogenous assay, that consists of a simple prepare and read method, without the requirement of separation or washing steps.

<span class="mw-page-title-main">Protein–ligand complex</span>

A protein–ligand complex is a complex of a protein bound with a ligand that is formed following molecular recognition between proteins that interact with each other or with other molecules. Formation of a protein-ligand complex is based on molecular recognition between biological macromolecules and ligands, where ligand means any molecule that binds the protein with high affinity and specificity. Molecular recognition is not a process by itself since it is part of a functionally important mechanism involving the essential elements of life like in self-replication, metabolism, and information processing. For example DNA-replication depends on recognition and binding of DNA double helix by helicase, DNA single strand by DNA-polymerase and DNA segments by ligase. Molecular recognition depends on affinity and specificity. Specificity means that proteins distinguish the highly specific binding partner from less specific partners and affinity allows the specific partner with high affinity to remain bound even if there are high concentrations of less specific partners with lower affinity.

References

  1. 1 2 3 4 5 Blake, Robert C.; Pavlov, Andrey R.; Blake, Diane A. (1999). "Automated Kinetic Exclusion Assays to Quantify Protein Binding Interactions in Homogeneous Solution". Analytical Biochemistry. 272 (2): 123–134. doi:10.1006/abio.1999.4176. PMID   10415080.
  2. 1 2 3 4 5 Darling, Ryan J.; Brault, Pierre-Alexandre (2004). "Kinetic Exclusion Assay Technology: Characterization of Molecular Interactions". ASSAY and Drug Development Technologies. 2 (6): 647–657. doi:10.1089/adt.2004.2.647. ISSN   1540-658X. PMID   15674023.
  3. 1 2 Glass, Thomas R.; Winzor, Donald J. (2014). "Confirmation of the validity of the current characterization of immunochemical reactions by kinetic exclusion assay". Analytical Biochemistry. 456: 38–42. doi:10.1016/j.ab.2014.04.011. PMID   24751468.
  4. 1 2 3 4 Bee, Christine; Abdiche, Yasmina N.; Stone, Donna M.; Collier, Sierra; Lindquist, Kevin C.; Pinkerton, Alanna C.; Pons, Jaume; Rajpal, Arvind (2012-04-30). "Exploring the Dynamic Range of the Kinetic Exclusion Assay in Characterizing Antigen-Antibody Interactions". PLOS ONE. 7 (4): e36261. Bibcode:2012PLoSO...736261B. doi: 10.1371/journal.pone.0036261 . ISSN   1932-6203. PMC   3340344 . PMID   22558410.
  5. 1 2 3 Rathanaswami, Palaniswami; Richmond, Karen; Manchulenko, Kathy; Foltz, Ian N. (2011-07-01). "Kinetic analysis of unpurified native antigens available in very low quantities and concentrations". Analytical Biochemistry. 414 (1): 7–13. doi:10.1016/j.ab.2011.02.034. ISSN   1096-0309. PMID   21371417.
  6. 1 2 3 Luginbühl, Béatrice; Kanyo, Zoltan; Jones, R. Mark; Fletterick, Robert J.; Prusiner, Stanley B.; Cohen, Fred E.; Williamson, R. Anthony; Burton, Dennis R.; Plückthun, Andreas (2006-10-13). "Directed evolution of an anti-prion protein scFv fragment to an affinity of 1 pM and its structural interpretation". Journal of Molecular Biology. 363 (1): 75–97. doi:10.1016/j.jmb.2006.07.027. ISSN   0022-2836. PMID   16962610.
  7. 1 2 3 4 Bee, Christine; Abdiche, Yasmina N.; Pons, Jaume; Rajpal, Arvind (2013-11-06). Kaveri, Srinivas (ed.). "Determining the Binding Affinity of Therapeutic Monoclonal Antibodies towards Their Native Unpurified Antigens in Human Serum". PLOS ONE. 8 (11): e80501. Bibcode:2013PLoSO...880501B. doi: 10.1371/journal.pone.0080501 . ISSN   1932-6203. PMC   3819287 . PMID   24223227.
  8. 1 2 Rathanaswami, Palaniswami; Babcook, John; Gallo, Michael (2008-02-01). "High-affinity binding measurements of antibodies to cell-surface-expressed antigens". Analytical Biochemistry. 373 (1): 52–60. doi:10.1016/j.ab.2007.08.014. ISSN   0003-2697. PMID   17910940.
  9. ↑ Rathanaswami, Palaniswami; Roalstad, Shelly; Roskos, Lorin; Su, Qiaojuan Jane; Lackie, Steve; Babcook, John (2005-09-09). "Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8". Biochemical and Biophysical Research Communications. 334 (4): 1004–1013. doi:10.1016/j.bbrc.2005.07.002. ISSN   0006-291X. PMID   16038881.
  10. ↑ Kielczewska, Agnieszka; D'Angelo, Igor; Amador, Maria Sheena; Wang, Tina; Sudom, Athena; Min, Xiaoshan; Rathanaswami, Palaniswami; Pigott, Craig; Foltz, Ian N. (2022-02-01). "Development of a potent high-affinity human therapeutic antibody via novel application of recombination signal sequence–based affinity maturation". Journal of Biological Chemistry. 298 (2): 101533. doi: 10.1016/j.jbc.2021.101533 . PMC   8808179 . PMID   34973336.
  11. ↑ Xie, Lei; Mark Jones, R.; Glass, Thomas R.; Navoa, Ryman; Wang, Yan; Grace, Michael J. (2005). "Measurement of the functional affinity constant of a monoclonal antibody for cell surface receptors using kinetic exclusion fluorescence immunoassay". Journal of Immunological Methods. 304 (1–2): 1–14. doi:10.1016/j.jim.2005.04.009. ISSN   0022-1759. PMID   16098983.
  12. 1 2 Fan, Yongfeng; Barash, Jason R.; Lou, Jianlong; Conrad, Fraser; Marks, James D.; Arnon, Stephen S. (2016-03-01). "Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H". Journal of Infectious Diseases. 213 (10): 1606–1614. doi:10.1093/infdis/jiv770. ISSN   0022-1899. PMC   4837907 . PMID   26936913.
  13. ↑ Köck, K; Pan, W J; Gow, J M; Horner, M J; Gibbs, J P; Colbert, A; Goletz, T J; Newhall, K J; Rees, W A; Sun, Y; Zhang, Y (2014-12-15). "Preclinical development of AMG 139, a human antibody specifically targeting IL-23". British Journal of Pharmacology. 172 (1): 159–172. doi:10.1111/bph.12904. ISSN   0007-1188. PMC   4280975 . PMID   25205227.
  14. ↑ Tabrizi, Mohammad A.; Bornstein, Gadi Gazit; Klakamp, Scott L.; Drake, Andrew; Knight, Richard; Roskos, Lorin (2009). "Translational strategies for development of monoclonal antibodies from discovery to the clinic". Drug Discovery Today. 14 (5–6): 298–305. doi:10.1016/j.drudis.2008.12.008. ISSN   1359-6446. PMID   19152840.
  15. ↑ Kariolis, Mihalis S.; Miao, Yu Rebecca; Jones, Douglas S.; Kapur, Shiven; Mathews, Irimpan I.; Giaccia, Amato J.; Cochran, Jennifer R. (2014). "An engineered Axl 'decoy receptor' effectively silences the Gas6/Axl signaling axis". Nature Chemical Biology. 10 (11): 977–983. doi:10.1038/nchembio.1636. ISSN   1552-4450. PMC   4372605 . PMID   25242553.
  16. ↑ Kontermann, Roland, ed. (2012-03-14). Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA. doi:10.1002/9783527644827. ISBN   978-3-527-64482-7.
  17. ↑ Champagne, Kelly; Shishido, Akira; Root, Michael J. (2009-02-06). "Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil". The Journal of Biological Chemistry. 284 (6): 3619–3627. doi: 10.1074/jbc.M809269200 . ISSN   0021-9258. PMC   2635040 . PMID   19073602.
  18. ↑ Schiele, Felix; van Ryn, Joanne; Litzenburger, Tobias; Ritter, Michael; Seeliger, Daniel; Nar, Herbert (2015-06-05). "Structure-guided residence time optimization of a dabigatran reversal agent". mAbs. 7 (5): 871–880. doi:10.1080/19420862.2015.1057364. ISSN   1942-0862. PMC   4622598 . PMID   26047352.
  19. ↑ Chiu, Y. W.; Li, Q. X.; Karu, A. E. (2001-11-15). "Selective binding of polychlorinated biphenyl congeners by a monoclonal antibody: analysis by kinetic exclusion fluorescence immunoassay". Analytical Chemistry. 73 (22): 5477–5484. doi:10.1021/ac0102462. ISSN   0003-2700. PMID   11816577.
  20. ↑ Blake, Diane A.; Chakrabarti, Pampa; Khosraviani, Mehraban; Hatcher, Frank M.; Westhoff, Connie M.; Goebel, Peter; Wylie, Dwane E.; Blake, Robert C. (1996-11-01). "Metal Binding Properties of a Monoclonal Antibody Directed toward Metal-Chelate Complexes". Journal of Biological Chemistry. 271 (44): 27677–27685. doi: 10.1074/jbc.271.44.27677 . ISSN   0021-9258. PMID   8910359. S2CID   35192838.
  21. ↑ Leung, Elizabeth; Rohn, Troy; Fologea, Daniel (2018). "Quantifying Protein-DNA Interactions by Kinetics Exclusion Assay". Biophysical Journal. 114 (3): 442a. Bibcode:2018BpJ...114..442L. doi: 10.1016/j.bpj.2017.11.2445 .
  22. ↑ European Patent Office. "EP 2770058 A1 20140827 - Ligand and method for detection of okadaic acid". data.epo.org. Retrieved 2020-07-16.
  23. ↑ Fleming, Jonathan K.; Wojciak, Jonathan M. (2017), Pébay, Alice; Turksen, Kursad (eds.), "Measuring Sphingosine-1-Phosphate/Protein Interactions with the Kinetic Exclusion Assay", Sphingosine-1-Phosphate, vol. 1697, New York, NY: Springer New York, pp. 1–8, doi:10.1007/7651_2017_5, ISBN   978-1-4939-7412-2, PMID   28349502 , retrieved 2020-07-16
  24. ↑ Fleming, Jonathan K.; Glass, Thomas R.; Lackie, Steve J.; Wojciak, Jonathan M. (2016). "A novel approach for measuring sphingosine-1-phosphate and lysophosphatidic acid binding to carrier proteins using monoclonal antibodies and the Kinetic Exclusion Assay". Journal of Lipid Research. 57 (9): 1737–1747. doi: 10.1194/jlr.D068866 . ISSN   0022-2275. PMC   5003157 . PMID   27444045.
  25. ↑ Werkmann, D.; Buyse, M.-A.; Dejager, L.; Cornelis, S.; Thudium, C.S.; Karsdal, M.A.; Ladel, C.; Guehring, H.; Michaelis, M.; Lindemann, S. (2018). "In vitro characterization of the ADAMTS-5 specific nanobody® M6495". Osteoarthritis and Cartilage. 26: S178. doi: 10.1016/j.joca.2018.02.384 .
  26. ↑ Lou, Jianlong; Wen, Weihua; Conrad, Fraser; Meng, Qi; Dong, Jianbo; Sun, Zhengda; Garcia-Rodriguez, Consuelo; Farr-Jones, Shauna; Cheng, Luisa; Henderson, Thomas; Brown, Jennifer (2018-02-15). "A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A". Toxins. 10 (2): 84. doi: 10.3390/toxins10020084 . ISSN   2072-6651. PMC   5848185 . PMID   29462889. S2CID   3851016.
  27. ↑ Nowakowski, A. Wang, C. Powers, D. B. Amersdorfer, P. Smith, T. J. Montgomery, V. A. Sheridan, R. Blake, R. Smith, L. A. Marks, J. D. (2002). "Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody". Proceedings of the National Academy of Sciences of the United States of America. 99 (17). National Academy of Sciences: 11346–50. Bibcode:2002PNAS...9911346N. doi: 10.1073/pnas.172229899 . OCLC   678733610. PMC   123259 . PMID   12177434.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  28. ↑ Ohmura, Naoya; Lackie, Steve J.; Saiki, Hiroshi (2001). "An Immunoassay for Small Analytes with Theoretical Detection Limits". Analytical Chemistry. 73 (14): 3392–3399. doi:10.1021/ac001328d. ISSN   0003-2700. PMID   11476240.
  29. ↑ Glass, Thomas R.; Ohmura, Naoya; Saiki, Hiroshi (2007-03-01). "Least detectable concentration and dynamic range of three immunoassay systems using the same antibody". Analytical Chemistry. 79 (5): 1954–1960. doi:10.1021/ac061288z. ISSN   0003-2700. PMID   17256970.
  30. ↑ Li, Xin; Kaattari, Stephen L.; Vogelbein, Mary A.; Vadas, George G.; Unger, Michael A. (2016). "A highly sensitive monoclonal antibody based biosensor for quantifying 3–5 ring polycyclic aromatic hydrocarbons (PAHs) in aqueous environmental samples". Sensing and Bio-Sensing Research. 7: 115–120. doi:10.1016/j.sbsr.2016.02.003. PMC   4767017 . PMID   26925369.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.